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Abdominal aortic aneurysm (AAA) is an inflammatory vascular dis-
ease with high mortality and limited treatment options. How
blood lipids regulate AAA development is unknown. Here lipidomics
and genetic models demonstrate a central role for procoagulant en-
zymatically oxidized phospholipids (eoxPL) in regulating AAA. Spe-
cifically, through activating coagulation, eoxPL either promoted or
inhibited AAA depending on tissue localization. Ang II administra-
tion to ApoE −/−mice increased intravascular coagulation during AAA
development. Lipidomics revealed large numbers of eoxPL formed
within mouse and human AAA lesions. Deletion of eoxPL-generating
enzymes (Alox12 or Alox15 ) or administration of the factor Xa in-
hibitor rivaroxaban significantly reduced AAA. Alox-deficient mice
displayed constitutively dysregulated hemostasis, including a con-
sumptive coagulopathy, characterized by compensatory increase in
prothrombotic aminophospholipids (aPL) in circulating cell mem-
branes. Intravenously administered procoagulant PL caused clotting
factor activation and depletion, induced a bleeding defect, and sig-
nificantly reduced AAA development. These data suggest that Alox
deletion reduces AAA through diverting coagulation away from the
vessel wall due to eoxPL deficiency, instead activating clotting factor
consumption and depletion in the circulation. In mouse whole blood,
∼44 eoxPL molecular species formed within minutes of clot initia-
tion. These were significantly elevated with ApoE −/− deletion, and
many were absent in Alox−/− mice, identifying specific eoxPL that
modulate AAA. Correlation networks demonstrated eoxPL belonged
to subfamilies defined by oxylipin composition. Thus, procoagulant
PL regulate AAA development through complex interactions with
clotting factors. Modulation of the delicate balance between bleed-
ing and thrombosis within either the vessel wall or circulation was
revealed that can either drive or prevent disease development.
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Abdominal aortic aneurysms (AAA) form in the abdominalaorta and cause ∼11,000 deaths per year in the United
Kingdom and United States, due to sudden rupture (1, 2). There
are limited options to alter the natural history of AAA develop-
ment. Treatment usually requires surgery; however, these opera-
tions are associated with high rates of morbidity and mortality. A
recent metaanalysis indicated that genetic control of lipoprotein
levels alters the risk of developing AAA; however, the role of
bioactive inflammatory lipids is unknown (3).
Coagulation factor activation has been observed in human AAA,
and a potentially causative role in disease is suggested because
some anticoagulant drugs reduce AAA formation; however, the
mechanisms that underpin this are unknown (4–7). Lipids play an
important role in controlling blood clot formation. For hemostasis
to occur, coagulation factors must assemble on phospholipid (PL)
membranes leading to thrombin generation. Two classes of PL
work together to achieve coagulation, aminoPL (aPL) and enzy-
matically oxidized PL (eoxPL). aPL comprise phosphatidyletha-
nolamine (PE) and phosphatidylserine (PS), and both are absent on
the outer surface of resting blood cells. During injury, blood cells
including platelets externalize aPL, generating an electronegative
surface. The PS headgroup associates with calcium allowing binding
of coagulation factors (factors II, VII, IX, and X) to the cell surface,
increasing their local concentrations and allowing them to interact
(8–11). PS is essential, and its procoagulant activity is enhanced by
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PE (12, 13). A key role for aPL in supporting in vivo blood clotting
on the surface of eosinophils was demonstrated recently (14).
In the last 10 years, large families of oxidized PL generated by
circulating immune cells, macrophages, and platelets were dis-
covered. These are called eoxPL since they are generated in a
controlled manner by immune cell enzymes (15–21). eoxPL are
required for normal hemostasis in vivo and are elevated in hu-
man venous thrombosis (14, 17, 22). In isolated platelets, over
100 molecular species were recently identified using lipidomics,
and additional forms are generated by neutrophils and mono-
cytic cells (20). eoxPL are formed by lipoxygenases (LOX), of
which there are several immune cell isoforms. These are encoded
by ALOX15/Alox15 (human 15-LOX1, murine 12/15-LOX in
eosinophils, resident peritoneal macrophages, and IL4-treated
monocytes), ALOX12/Alox12 (12-LOX, platelets) and ALOX5/
Alox5 (5-LOX, neutrophils). There are also rarer isomers gen-
erated by cyclooxygenase-1 (COX-1, PTGS/Ptgs1) (15).
We recently elucidated the detailed biochemical mechanisms
by which eoxPL promote coagulation (17, 21, 22). On cell acti-
vation, these lipids are externalized to the outer plasma mem-
brane where they interact with clotting factors (21, 23). Using
multiple approaches, coagulation factors were shown to bind
eoxPL membranes, directly enhancing catalytic turnover (22).
Their electronegative oxidized fatty acid side chains enhance the
ability of PS to support clotting (22). When administered directly
at a site of injury, eoxPL support hemostasis in wild-type or
hemophilia A mice through provision of a local surface for co-
agulation factor binding and activation, where it is needed (17, 22).
We also recently found that Alox12−/− and Alox15−/− mice gener-
ate smaller venous thrombi and bleed excessively when challenged
and that hemostasis can be restored by local eoxPL injection into
damaged tissue (14, 17). However, it is not yet known which eoxPL
molecular species form during clot formation, the predominant
forms contributing to hemostasis/thrombosis, or how their inter-
actions with coagulation may influence vascular inflammation.
Herein, we hypothesize that eoxPL regulation of coagulation
may play a role in AAA development. To test this, we focused on
characterizing the generation and role of the procoagulant sur-
face provided by eoxPL in angiotensin II-driven disease, using
genetic murine models, oxylipidomics mapping of whole blood,
and analysis of human AAA tissue.
Results
Lipidomic Profiling Demonstrates Multiple eoxPL Species in Developing
AAA Lesions. To examine for the generation of procoagulant PL in
AAA lesions, molecular species of eoxPL were profiled using
targeted LC/MS/MS in aortic tissue from 19- to 24-wk-old chow-
fed male ApoE−/− mice administered 1.1 mg·kg−1 per day of
Ang II by osmotic minipump for 2 wk. A large number of eoxPL
were detected, including hydroxyoctodecadienoic acid (HODE);
hydroxydocosahexanoic acid (HDOHE); and 5-, 11-, 12-, and 15-
hydroxyeicosatetraenoic acid (HETE)-PL, including both phos-
phatidylethanolamines (PE) and phosphatidylcholines (PC) (Fig.
1A). In contrast, eoxPL were undetectable in aortic wall from
ApoE−/− mice not administered Ang II.
In a preliminary analysis, we examined for eoxPL generation
in human AAA and its mural thrombus. Here six patient samples
were divided into aortic wall, inner thrombus (closest to lumen),
and outer thrombus (closest to aneurysm wall) (Figs. 1 B and C
and 2 A and B and SI Appendix, Fig. S1). Despite AAA patients
varying due to age, demographics, and genetic background, there
were clear similarities between donors, with the same lipid species
generally predominating. For all samples, eoxPL were detected in
thrombus and AAA wall, with a trend toward higher levels and
greater diversity in the thrombi. Focusing on HETE-PLs, molec-
ular species containing 12- or 5-HETEs were primarily detected in
thrombus (from 12-, 5-LOXs in platelets and neutrophils), while
15-HETE-PLs (from 15-LOX in eosinophils and monocytes) were
found in all locations (Fig. 1B). As a representative dataset, inner
thrombus from patient 4 contains three HETE-PE molecular
species with each comprising two abundant isomers containing 12-
and 15-HETE (Fig. 1C and SI Appendix, Fig. S1). Representative
chromatograms are shown for two 5-HETE-PEs for patients 1 and
5 (Fig. 2A). OxPL containing truncated PUFA were found in
AAA wall and thrombi (Figs. 1B and 2B). Truncated species may
form via nonenzymatic fragmentation of enzymatically generated
full-length eoxPL. This preliminary analysis, which supports the
idea that eoxPL are a component of human AAA, now needs to
be repeated using larger numbers of AAA samples, enabling
deeper characterization and correlation with clinical stage, medi-
cation, inflammatory markers, gene expression, etc.
AAA Development Is Significantly Reduced in ApoE−/− Mice Lacking
Either Alox12 or Alox15. Since eoxPL were detected in AAA tissue,
we tested whether genetic deletion of two Alox isoforms that
generate this class of lipids in isolated blood cells affects lesion
development (18, 21, 24). We specifically focused on Alox12
(platelets, 12-LOX) and Alox15 (leukocytes, 12/15-LOX).
ApoE−/− mice were backcrossed, generating ApoE−/−/Alox12−/−
and ApoE−/−/Alox15−/− double knockout strains. These were first
confirmed to be resistant to atherosclerosis development, as
described in SI Appendix, Fig. S2. Next, to examine the effect of
Alox-deletion on AAA, Ang II was administered to male or fe-
male ApoE−/−, ApoE−/−/Alox12−/−, or ApoE−/−/Alox15−/− mice
for 2 wk, as above. For both Alox-deficient strains, AAA devel-
opment was markedly reduced in male and absent in female mice
(Fig. 2 C and D and SI Appendix, Figs. S3–S5). This demonstrates
that both isoforms can independently contribute to disease de-
velopment. This protection was independent of blood pressure
(BP) and plasma lipoprotein levels since a significant BP elevation
was seen in all strains at day 11, while there was no effect of Alox
deletion on total cholesterol with/without Ang II treatment (SI
Appendix, Fig. S6A and Tables S1 and S2). Overall, the disease
burden in females was lower, in line with previous studies; thus,
protection against AAA was more complete in that gender (25).
Direct Inhibition of FXa Significantly Reduced AAA Development in
Vivo.An involvement of coagulation in AAA development has been
suggested (7), and we recently demonstrated that eoxPL, specifi-
cally HETE-PEs and HETE-PCs, bind to and support clotting
factor activities (17, 22). To test whether AAA is dependent on
coagulation factor activity in this model, we administered the direct
FXa inhibitor rivaroxaban via chow to male ApoE−/− mice during
Ang II administration and found significantly less AAA developed
(SI Appendix, Fig. S6B). This suggested a mechanism by which
Alox15 and Alox12 could promote AAA development, where eoxPL
generated at the vessel wall during lesion progression provide a
procoagulant surface for clotting factor binding and activation. This
idea was next investigated by characterizing coagulation activity in
the Alox-deficient mouse strains basally and during Ang II infusion.
Alox12 or Alox15 Deficiency Disrupts Coagulation in Wild-Type or
ApoE−/− Mice. Circulating thrombin-anti-thrombin (TAT) com-
plexes were increased approximately twofold in ApoE−/− versus
wild type, although this was not significant (Fig. 3A). However, in
either wild-type or ApoE−/− mice, genetic deletion of either
Alox12 or Alox15 led to approximately fivefold elevations in
TATs (Fig. 3A), indicating significantly higher levels of thrombin
generation in Alox-deficient mice. We next measured pro-
thrombin time (PT) following addition of tissue factor-
containing PL to platelet poor plasma (PPP). This is sensitive
to levels of clotting factors II, VII, IX and X, and increases with
relative factor deficiency, with a value of 120 s reflecting severe
coagulopathy. Overall, PT significantly increased in both wild-
type and ApoE−/− mice following deletion of Alox12 or Alox15
(Fig. 3B). Both TAT and PT values in Alox−/− single or double
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Fig. 1. EoxPL are detected in ApoE−/−mouse and human AAA tissue. (A) Lipidomics shows eoxPL in murine AAA. Lipids from abdominal aorta harvested from
ApoE−/− mice following Ang II was analyzed using LC/MS/MS, as in SI Appendix, SI Materials and Methods (each sample represents a different aorta). (B)
Lipidomics reveals eoxPL in human AAA. Abdominal aorta were harvested from six male patients, and lipids were analyzed using LC/MS/MS. Heatmaps were
generated using Pheatmap as described in SI Appendix, SI Materials and Methods (each sample represents a different sample), shown as log10 values for
analyte:internal standard normalized to tissue weight (mg). (C) Representative chromatograms show 18:0p/HETE-PE lipids, with a predominance of eoxPL
from either Alox15 or Alox12.Middle showsm/z 766.6/319.2, detecting all HETE-PE isomers and revealing two main products. These are confirmed as 15-HETE-
PE (13.7 min) or 12-HETE-PE (14.2 min), by detecting internal daughter ions at m/z 219.1 or 179.1, respectively.
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knockouts showed far higher variability than either wild-type or
ApoE−/− mice, indicating that the extent of Alox−/−-associated
coagulopathy varies between individual mice. Also, the effect of
Alox deletion was not affected by ApoE deficiency. These find-
ings demonstrate an intravascular consumptive coagulopathy.
Since this occurs in the absence of vascular inflammatory chal-
lenge, it indicates that Alox12- or Alox15-deficient mice exhibit
chronic defective coagulation under basal conditions. Potential
explanations for this finding were sought, as given below. There
was a higher variation of both PT and TAT in both Alox-deficient
strains. We believe this is due to variable penetrance of the phe-
notype, a not uncommon feature of genetically modified mouse
strains (26–28). The biological reasons in these strains are unknown.
Deficiency of Alox12−/− or Alox15−/− Increases PE Externalization on
the Surface of Platelets or Eosinophils. Consumptive coagulopathy
in Alox12−/− and Alox15−/− mice was initially unexpected since
these mice are deficient in procoagulant eoxPL lipids (17, 24).
However, we note that depletion of coagulation factors could at
least in part explain the protective AAA phenotype since the
model is FXa dependent (SI Appendix, Fig. S6B). To explore
mechanisms, we examined exposure of procoagulant aPL on the
surface of washed platelets or eosinophils (derived from bone
marrow progenitors) from Alox12−/− or Alox15−/− mice, re-
spectively. Alox15−/− eosinophils externalized significantly more
PE on ADP activation (Fig. 3C), while Alox12−/− platelets ex-
ternalized significantly more PE without stimulation (Fig. 3D).
These data suggest that deficiency of eoxPL is overcompensated
for by elevation in aPL externalization in circulating cells. This is
likely to lead to activation of coagulation, increased thrombin
generation and depletion of clotting factors within the circula-
tion, as was indeed observed in these mice.
Coagulation Is Activated During AAA Development and Modulated by
Genetic Deficiency of Alox Isoforms. Given the requirement for
coagulation in driving Ang II-dependent AAA and the basal
clotting defects in Alox−/− mice, the effect of Ang II infusion on
systemic coagulation and how this is modulated by Alox deletion
was next characterized.
First, we found that Ang II infusion mediated significant in-
creases in plasma TATs in ApoE−/− mice, along with more var-
iable TAT levels in this group (Fig. 4A). While PT did not
increase significantly, wide variability in PT was also seen fol-
lowing Ang II infusion (Fig. 4B). Indeed, several mice (5 out of
9) showed the maximum of 120 s (assay termination), versus only
1 of 14 in the control ApoE−/− group. Together, this indicates
that Ang II stimulates a consumptive coagulopathy during AAA
development in the majority of mice. Given the protective effect
of rivaroxaban and localization of eoxPL (Fig. 1A and SI Ap-
pendix, Fig. S6B), coagulation factors are likely activated at the
vessel wall and may drive lesion development through so far
uncharacterized inflammatory mechanisms.
In contrast, ApoE−/−/Alox15−/− and ApoE−/−/Alox12−/− mice
showed no significant changes in TATs following Ang II treat-
ment (Fig. 4A). Also, PT values were not consistently altered in
ApoE−/−/Alox15−/− or ApoE−/−/Alox12−/− strains, respectively, by
Ang II (Fig. 4B). However, both TATs and PT were already
significantly elevated in both double knockout strains before Ang
II infusion, compared with ApoE−/− alone (Fig. 3 A and B). Thus,
in the double knockout strains, these data may simply reflect
both ApoE- and Alox-dependent coagulation taking place at the
same time. Notably, while wild-type or ApoE−/− mice showed a
low level of variation between individuals, the extent of coagul-
opathy seen with either Ang II or Alox deficiency was highly
variable between individual mice.
Overall, these data indicate that Ang II-driven AAA is associ-
ated with an acute consumptive coagulopathy that promotes lesion
development. However, conversely, the chronic coagulopathy seen
in Alox deficiency is associated with protection. Although this may
seem paradoxical, these different outcomes may reflect different
localizations of coagulation. Specifically, acute Ang II-driven co-
agulation is expected to be vessel wall localized (SI Appendix,
Scheme S1A), while in Alox deficiency, basal activation of co-
agulation and factor consumption may occur on the aPL-exposing
surface of circulating blood cells/platelets (SI Appendix, Scheme
S1 B and C). This chronic activation of coagulation seen in Alox−/−
mice may then lead to a relative lack of factors available to locally
bind and stimulate vascular inflammation in the vessel wall in
response to Ang II, thus dampening AAA development in double
knockout mice.
Lipidomics Reveals Complex Regulation of eoxPL by ApoE, Alox12,
and Alox15 During Coagulation. The endogenous molecular spe-
cies of eoxPL that support AAA development in vivo are unknown,
although several candidates were detected in lesions (Fig. 1). To
delineate which originate from Alox12 or Alox15 and the effect of
vascular inflammation, oxylipidomics of a forming murine thrombus
comparing all six murine strains was performed. Since Alox−/−mice
A B
C
D
Fig. 2. The 12- and 15-LOX–derived eoxPL are detected in human AAA
thrombus, while Alox12 or Alox15 deletion prevents AAA. (A) Representative
chromatograms showing a truncated PE and PC both detected in AAA wall. (B)
Representative chromatograms of eoxPL generated by leukocyte 5-LOX, in
AAA wall. (C and D) Alox15 or Alox12 deletion reduces AAA development in
ApoE−/−mice. Male (C) or female (D) ApoE−/−, ApoE−/−/Alox15−/−, and ApoE−/−/
Alox12−/−mice aged 19–24 wk were infused with Ang II for 2 wk. Aortae were
imaged as described in Materials and Methods. Representative aortae are
shown (Left), including a PBS control for each condition. The full datasets are
provided in SI Appendix, Figs. S3–S5. Incidence of AAA as percent of group is
shown (Right). Data are analyzed using Fisher’s exact test and expressed as
percent AAA, ***P < 0.001, **P < 0.01.
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are protected against AAA, it is not possible to obtain sufficient
lesional tissue from double knockout mice; thus, blood was used as
a surrogate tissue. Murine whole blood was induced to clot by TF in
vitro, modeling a low-shear venous-type thrombus, containing
plasma, white cells, red cells, and platelets. In wild-type blood,
44 eoxPL including both PEs and PCs formed, peaking around 15–
20 min, then declining back to baseline (Fig. 4C). In contrast,
ApoE−/− blood responded in an exaggerated manner, generating
higher levels of eoxPL that remained elevated for longer.
In contrast, clots from Alox12−/− or Alox15−/− mice lacked
large numbers of eoxPL, in particular several HETEs, HDOHEs,
and monohydroxy forms of adrenic (22:4) and eicosapentanoic
(22:5) acids, and these remained low when mice were back-
crossed to ApoE−/− (Fig. 4C). Notably, these tend to be longer-
chain PUFA, which are classical substrates for Alox isoforms.
The same lipids were largely reduced in both strains, and this is
expected since 12-LOX and 12/15-LOX display almost identical
enzymatic activities. A group of lipids that were enriched in 5-
and 15-HETEs, most likely from neutrophils in mice (e.g., from
Alox5 or Ptgs1), was reduced in Alox12−/− or Alox15−/− mice;
however, backcrossing to ApoE−/− restored their levels (Fig. 4C).
This suggests a positive influence of Alox12/Alox15 on neutrophil
activation during blood clotting. Last, a family of eoxPL enriched
in HODEs of unknown origin is somewhat elevated in Alox12−/−-
or Alox15−/−-deficient clots (versus wild type), and these were
only partially influenced by ApoE−/− status.
Hierarchical clustering of heatmap lipids shows significant
grouping based on the Sn2 oxylipin structure (Fig. 4C). Com-
paring the pattern and abundance of eoxPL signals, we suggest
that the molecular species most likely to interact with co-
agulation factors driving AAA in vivo are HETE-PEs (Fig. 4C).
Thus, we next focused on measuring these isoforms in all strains
during clot formation, using a targeted quantitative assay.
HETE-PEs Are Elevated in ApoE−/− During Clotting but Decrease on
Backcrossing to Alox12−/− or Alox15−/−. HETE-PE species were
quantified as a subgroup of eoxPL, using biogenic standards.
ApoE−/− clots generated twice the levels as wild type (SI Ap-
pendix, Fig. S7A). However, Alox12−/− or Alox15−/− deficiency,
either wild type or on ApoE−/− background, significantly reduced
total HETE-PEs (SI Appendix, Fig. S7A). In particular, Alox12−/−
reduced HETE-PEs back to approximately wild-type levels in
ApoE−/− mice. These data further support the idea that HETE-
PEs represent the eoxPL primarily responsible for the effect of
Alox on AAA development.
Multivariate Analysis Reveals eoxPL That Describe Mouse Strain
Differences During Clot Formation. Next, the full eoxPL dataset
was statistically analyzed using principle component analysis in
3D (SI Appendix, Fig. S7B). Unclotted blood from all strains (t =
0 min) grouped closely (solid short arrows), indicating similar
lipid composition. Once coagulation was initiated, divergence
was seen, and this was strongly influenced by genotype. At the
end (t = 180 min), most strains are found in separate regions of
the plot indicating different lipid compositions (dashed long
arrows). A loadings plot indicates that most eoxPL have a strong
positive influence in PC1 (SI Appendix, Fig. S7C). Notably,
headgroup did not influence loadings in either PC1 or PC2.
However, fatty acyl at Sn2 has a clear influence in PC2, with 5-,
15-HETEs, 20:5(O), and HODE generally having a positive ef-
fect (above the line), while 12-HETEs, HDOHEs, 22:4(O), and
22:5(O) had a negative effect (below the line). This indicates that
longer-chain PUFA eoxPL are generated as a related group
(negative in PC2), versus shorter chain more saturated (positive
in PC2). We next explored this further using Cytoscape analysis,
which correlates individual lipids with each other.
EoxPL Cytoscape Analysis Reveals Subgroups of Molecular Species
Based on Enzymatic Source. Using Cytoscape, a correlation plot
was generated, where nodes (circles) represent lipids, with edges
(lines) representing the strength of correlation (SI Appendix, Fig.
S7D). Size of node represents the number of correlations, with
larger nodes meaning a higher number of edges per lipid. eoxPL
were assigned to 12-LOX if absent in Alox12−/− clots (SI Appendix,
Fig. S7D). The 5-LOX (Alox5)-derived products were assigned by
the presence of 5-HETE at Sn2. PE(18:1p/12-HETE) and PE
(18:1p/15-HETE) were assigned as “LOX”-derived based on
their absence in at least one Alox deficient strain. This analysis
shows that lipids from Alox12 are strongly correlated, while
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Fig. 3. Alox12 −/− or Alox15 −/− mice show disruption of the thrombosis/
bleeding axis, with increased aPL externalization in circulating blood cells.
(A) Alox12 or Alox15 deficiency promotes thrombin generation in vivo in
wild-type and ApoE−/− mice. Plasma from 19-wk-old mice was isolated as in
Materials and Methods. Thrombin/anti-thrombin (TAT) complexes were
measured using ELISA. (B) Alox12 or Alox15 deficiency reduces clotting in
wild-type and ApoE−/− mice. Mouse plasma obtained as in B was tested for
PT as in Materials and Methods. For A and B, data were analyzed using
Mann–Whitney nonparametric u test and shown on box plots (median, with
whiskers representing interquartile range), ***P < 0.001, **P < 0.01, *P <
0.05. (C) Eosinophils from Alox15−/−mice externalize more PE than wild type
on ADP activation. Eosinophils generated as described in Materials and
Methods were activated using 40 μM ADP before PE externalization de-
termined (n = 3, mean ± SEM). (D) Platelets from Alox12−/− mice externalize
more PE than wild type on thrombin activation. Mouse platelets were iso-
lated as described in Materials and Methods, and PE externalization was
determined. Data were analyzed using Student’s t test and expressed as
mean ± SEM (n = 10). **P < 0.01, *P < 0.05 (n = 10).
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5-HETE-PLs from Alox5 cluster together in the middle. HODE-PLs
form a separate group, to the left of the correlation plot. This in-
dicates that eoxPL with the same Sn2 fatty acid composition are
regulated together. Along with the heatmap and principal compo-
nent analysis (PCA), this reveals coordinated regulation of bio-
synthesis and metabolism and suggests that eoxPL subfamilies arise
from differentially regulated cellular and enzymatic pathways during
mouse blood clot formation, including the reesterification pathways
that attach eicosanoids to lysophospholipids.
Exogenous eoxPL or aPL Protect ApoE−/− Mice Against Ang II-Induced
AAA in Vivo and Influence Coagulation Regulation in Vivo. We next
tested whether eoxPL/aPL administration would alter the de-
velopment of AAA in vivo, using HETE-PEs that are found in
either platelets or eosinophils, from Alox12 or Alox15 in mice,
respectively. Recently, acute eoxPL administration (1 h) was
found to significantly elevate TATs, consistent with stimulating
coagulation in vivo (22). Thus, we hypothesized that eoxPL ad-
ministration over 2 wk might bind and activate circulating clot-
ting factors, diverting coagulation from the vessel wall and
potentially reducing AAA. Up to now, procoagulant liposomes
have not been administered to mice long term, and their effect
on hemostatic parameters is not known.
For this, tissue factor/phosphatidylcholine liposomes contain-
ing PS/PE (aPL liposomes), or the same liposomes with PE
replaced with 12-HETE-PE (eoxPL) (10 ng per injection), were
A B
C
Fig. 4. Ang II infusion induces consumptive coagulopathy in mice, while ApoE and Alox deletion is associated with major changes in eoxPL profile. (A) Ang II
increases plasma TATs in mice. ApoE−/−, ApoE−/−/Alox12−/−, and ApoE−/−/Alox15−/− 19- to 24-wk-old male mice maintained on a normal chow diet were
infused with Ang II for 2 wk. TATs were measured by ELISA. (B) PT of plasma in response to 2-wk infusion of Ang II with/without liposomes. ApoE−/−, ApoE−/−/
Alox12−/−, and ApoE−/−/Alox15−/− 19- to 24-wk-old male mice maintained on a normal chow diet were administered Ang II for 2 wk. PT was measured as per
Materials and Methods. Data were analyzed using Mann–Whitney nonparametric u test and shown on box plots (median, with whiskers representing
interquartile range), ***P < 0.001, *P < 0.05. (C) Oxylipidomics of blood clotting from all mouse strains. Blood was harvested and induced to clot as in
Materials and Methods. Lipids were extracted from clots and profiled using LC/MS/MS. Heatmaps were generated using Pheatmap (n = 3 per sample) using
log10 data values as described in SI Appendix, SI Materials and Methods.
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administered i.v. to male ApoE−/− mice every second day during
the Ang II infusion. In this experiment, aPL liposomes will have
some procoagulant activity but significantly less than for eoxPL
(22). As predicted, both formulations reduced AAA develop-
ment; however, this was only statistically significant for eoxPL
(Fig. 5A). We also administered liposomes to ApoE−/− mice also
lacking Alox12 or Alox15 and found a nonsignificant trend for
further protection (Fig. 5 B and C and SI Appendix, Figs. S8–
S10). Overall, this indicates that systemic provision of a pro-
coagulant PL membrane surface reduces AAA development,
with the level of protection being significantly higher with eoxPL.
Next, the effect of 2 wk eoxPL administration on plasma TAT
levels was determined, during Ang II infusion. Here eoxPL or
aPL administration to ApoE−/− mice dampened the Ang II-
dependent increase in plasma TATs, and this was statistically
significant for eoxPL (Fig. 5D). Overall, this is in line with the
idea that systemic eoxPL induce activation of coagulation in the
circulation and hence divert activated clotting factors from
the vessel wall, dampening the Ang II-dependent coagulopathy
that is required for AAA development. While we previously
found that acute eoxPL administration elevates TATs within 1 h,
the overall effect on coagulation parameters of chronic eoxPL
administration is not known, and further studies are required,
measuring levels of individual clotting factors and their locali-
zation within the tissue compartments to delineate the underly-
ing mechanisms responsible in this model.
i.v. Administration of Procoagulant Liposomes Induces an Acute
Bleeding Phenotype. Our in vivo studies suggested that procoa-
gulant lipids can be either causative (endogenous in the vessel
wall) or preventative (exogenous in the systemic circulation) for
AAA development (Figs. 2 and 5). To test this idea, we used
hemostasis as an outcome that reports on local or systemic co-
agulation activity, testing the effect of eoxPL/aPL administration
on tail bleeding. We showed recently that eoxPL injected locally
into tail tissue prevents bleeding in wild-type mice or several
strains with bleeding disorders including hemophilia A (17, 22).
This is because the procoagulant surface is provided where it is
needed at the cut site (17). However, in contrast, following acute
i.v. injection of eoxPL into wild-type mice, tail-bleeding time
significantly increased (Fig. 5E). Thus, eoxPL local administra-
tion promotes bleeding arrest, while systemic administration
leads to a bleeding defect. Since acute i.v. eoxPL also cause TAT
elevation, these data support the idea that systemic liposomes
cause activation and consumption of coagulation factors (22).
This is distinct from the effect of tissue-localized clotting factor
activity that drives AAA in response to Ang II, despite both el-
evating circulating TATs. Clotting factor removal from the cir-
culation can thus divert coagulation away from the vascular wall
effectively dampening its local activities.
Genetic Deficiency of Alox15 Suppresses Inflammation During AAA
Development in Mice. A recent study identified a central role for
coagulation in driving inflammatory responses in the vessel wall
during Ang II-driven disease (29). Thus, we explored whether the
deletion of Alox15 could regulate expression of Il6 and Ccl2/Ccr2
in aortic tissue during development of AAA. Il6 and Ccl2 were up-
regulated during Ang II infusion in ApoE−/− mice (Fig. 5F).
However, this response was significantly reduced in ApoE−/− mice
lacking Alox15, and in the case of Ccl2 a small decrease was noted.
In contrast, Ccr2 was relatively unaffected by Ang II in either
strain (Fig. 5F). Overall, these data suggest that eoxPL can support
the development of inflammation associated with Ang II-driven
AAA, although further work is required to fully delineate the
mechanisms involved and how this is mediated by clotting factors.
Discussion
The role of the procoagulant surface provided by circulating
blood cells and required for hemostasis has not been investigated
in the context of AAA. Here, using genetically modified mouse
models, human AAA tissue, and oxylipidomics, we demonstrate
A B C
D E
F
Fig. 5. Procoagulant liposomes prevent AAA in mice, while modulating
Ang II induced coagulation activities, and Alox15 deficiency is associated
with decreased Ang II induction of IL6 and Ccl2. (A) eoxPL/aPL liposomes
prevent AAA in ApoE−/−mice. Male ApoE−/−mice on normal chow diet aged
19–24 wk were administered Ang II as described in Materials and Methods.
Liposomes (eoxPL or aPL) were administered every second day (seeMaterials
and Methods for composition and dose). Data are expressed as percentage
of mice developing AAA. (B and C) eoxPL/aPL liposomes reduce AAA in
ApoE−/− mice lacking either Alox12 or Alox15. Male mice on normal chow
diet aged 19–24 wk were administered Ang II with/without liposomes as in C.
Data are expressed as percentage of mice developing AAA. For A–C, the full
dataset of aortae are shown in SI Appendix, Figs. S3 and S8–S10). (D) eoxPL
liposomes alter coagulation parameters during Ang II infusion into ApoE−/−
mice. ApoE−/− 19- to 24-wk-old male mice maintained on a normal chow diet
were infused with Ang II for 2 wk, and every second day, mice eoxPL or aPL
liposomes were administered as described in Materials and Methods. TATs
were measured by ELISA. (E) Systemic administration of eoxPL/aPL liposomes
promotes bleeding inmice. Male wild-type mice (11 wk old) were anesthetized
and i.v. injected with liposomes, and tail bleeding was measured after 1 h, as
described in Materials and Methods. Data from A–C were analyzed using
Fisher’s exact test, and data from D and Ewere analyzed using Mann–Whitney
nonparametric u test. ***P < 0.001, **P < 0.01, *P < 0.05; NS, no significance.
Data are shown on box plots (median, with whiskers representing interquartile
range). (F) Alox15 deficiency reduces the Ang II-induced elevation in IL6 and
Ccl2 in mouse AAA tissue. RNA was isolated from ApoE−/− AAA tissues as
detailed in Materials and Methods (n = 4 for all groups) and analyzed using
the RT2 Profiler PCR Array for Mouse Inflammatory Response and Autoim-
munity. Data are shown as ΔΔCT, expressed as fold change between control
and Ang II-treated mice, and compared using Student’s t test. ***P < 0.005.
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that the eoxPL/Alox axis is active and promotes development of
AAA in wild-type mice with up-regulation of IL6/CCL2. This
suggests a central role for bioactive lipids in AAA through reg-
ulating coagulation and its associated inflammation.
Murine models of AAA have been used for many years, and
while they do not fully replicate the human disease, a major
problem in the field is a lack of ability to follow the natural
history of AAA in humans. Animal models reproduce in-
flammation, extracellular matrix (ECM) destruction, and aortic
dilatation, all of which are seen in human aortic aneurysm (30).
Similar to human disease, the Ang II/ApoE model shows pref-
erence for males and stimulates an inflammatory response,
macrophage accumulation, and thrombosis (25). Here eoxPL
and oxPL are detected in both murine and human AAA tissue
and associated thrombus, indicating their presence at the site of
disease development in both species (Figs. 1 and 2 A and B).
How thrombosis and coagulation contribute to AAA in hu-
mans is not understood; however, consumptive coagulopathy
(CC) coexists with a variety of aneurysms, including presenting as
disseminated intravascular coagulation (DIC) (31). This suggests
pathological involvement in AAA, which our studies begin to
characterize. In some patients, CC/DIC preceded and led to the
diagnosis of AAA (31). In one report, a patient with stable an-
eurysm and chronic CC reverted to normal factor levels follow-
ing repair surgery (32). Many patients experience (aneurysm-
induced) DIC perioperatively (40–80%), considerably more
than would be expected for routine surgery, further supporting
the idea that the coagulation system is not normal in these pa-
tients. Last, focal accumulation of radiolabeled platelets in the
AAA lesion in 78% of stable patients has been reported, in-
dicating a functionally active consumption focus locally, in line
with our hypothesis (33). This strongly supports the notion that
factor activation in the lesion is a key feature of the disease,
although identifying the exact site of thrombin generation remains
a significant challenge. Indeed, thrombin generation can be sus-
tained by isolated smooth muscle cells, in a PAR-3– or PAR-4–
dependent manner, and is elevated in vitro in cells from hyper-
tensive rats, which are known to be more susceptible to thrombosis
in vivo (7, 33). The percentage of patients with DIC along with
AAA is unknown since most cases are considered asymptomatic
and only uncovered during the perioperative workup. Relating to
inflammation, it has been estimated that around 5–10% of human
AAAs are characterized by a significant inflammatory component,
including an immune response, inflammatory markers, and a cuff
of soft tissue inflammation surrounding the lesion (34).
Two mechanisms likely contribute to the protective effect of
Alox deletion. First, in wild-type mice, deposition of procoagulant
eoxPL within the vessel wall will support factor binding and acti-
vation locally, driving AAA. In support, Ang II infusion into
ApoE−/− mice is associated with factor activation, AAA is sensitive
to FXa inhibition, and numerous eoxPL from both platelets and
leukocytes were present in AAA lesions (Figs. 1 and 4 and SI
Appendix, Fig. S6B). Furthermore, both Alox12−/− and Alox15−/−
mice were both protected in this model, supporting a role for both
platelet and leukocyte-derived eoxPL in AAA development (Fig.
2). Indeed, Ang II is already known to drive leukocyte adhesion to
the vessel wall during AAA development and platelet activation
(35–37). We recently found that platelet/leukocyte eoxPL promote
thrombin generation in plasma (22). Monocyte/eosinophil or
platelet 15- or 12-HETE-PLs are more potent at promoting
thrombin generation (including ETP) than neutrophil 5-HETE-PL
analogs, although all were active (22). Thus, we propose that eoxPL
become deposited on the surface of the vessel wall, and these then
provide a localized surface to enable coagulation factor binding and
activation. The focal accumulation of radiolabeled platelets in the
AAA lesion in stable human patients supports this idea (33). Last,
neither Alox12 or Alox15 isoforms are expressed by smooth muscle
or endothelium ruling these out as a potential source of eoxPL.
Second, Alox−/− mice had a consumptive coagulopathy within
the circulation that could reduce coagulation factor availability
(Fig. 3 A and B). This is evidenced by higher TATs and in-
travascular depletion of clotting factors (prolonged PT), along
with increases in circulating blood cell externalized aPL (Fig. 3 C
and D and SI Appendix, Scheme S1B). Along with this, injection
of procoagulant PL into the circulation, recently shown to
acutely increase coagulation in vivo (22), caused a consumptive
coagulopathy and reduced AAA incidence, similar to the pro-
tective effects of either Alox deletion or factor Xa inhibition
(Figs. 2 and 5 and SI Appendix, Fig. S6B and Scheme S1). This
provides strong evidence that diverting coagulation factors from
the vessel wall prevents AAA development, highlighting the im-
portance of tissue localization of bioactive lipids. Importantly,
eoxPL/aPL can either promote or prevent AAA development,
dependent on their mode of generation/delivery and site of action.
Alox12 and Alox15 gene products (12-LOX and 12/15-LOX)
generate similar eoxPL isomers, specifically the abundant 12-
HETE-PLs, and our lipidomics analysis suggests these are the
most likely candidates for driving AAA in the vessel wall (Fig. 1
and SI Appendix, Fig. S7A) (18, 21, 24). This suggests potential
molecular determinants that could be modified for therapeutic
purposes. We note that while Alox12−/− has a more profound
effect on eoxPL levels, overall phenotypic outcome was similar
with either strain. Hemostasis is a complex process during which
the communication of distinct cell populations is not fully un-
derstood. Here genetic deletion of a single enzyme in platelets or
myeloid cells leads to striking similarities in both health/disease
phenotype and lipid mediator synthesis in blood. Along with our
observation of knock-on effects of Alox12 or Alox15-deletion on
Alox5 from neutrophils, this suggests that distinct blood cell types
cooperate closely to orchestrate thrombosis in vivo.
We recently found that Alox12−/− and Alox15−/−mice generate
smaller venous thrombi and bleed excessively when challenged
and that hemostasis can be restored by local eoxPL injection into
damaged tissue (14, 17). We proposed this resulted from de-
ficiency in procoagulant eoxPL generated by platelets and eosin-
ophils. Herein, we additionally show that both Alox−/− strains have
elevated basal TAT and PT, along with increased circulating levels
of externalized aPL on blood cells (Fig. 2). This demonstrates
higher endogenous rates of thrombin activation, with consumptive
coagulopathy apparent in vivo under healthy conditions. This
provides a second reason for a bleeding phenotype, whereby de-
pletion of coagulation factors reduces their availability for sup-
porting hemostasis. This is further supported by our observation
that acute systemic injection of eoxPL causes consumptive coa-
gulopathy and results in a bleeding phenotype (Fig. 5) (22).
Recently, a link between FXa generation and AAA was
demonstrated in mice since enoxaparin or fondaparinux atten-
uated disease development, and it was suggested that hyperco-
agulability promotes, while inhibition of coagulation is protective
(7). However, this does not take into account that thrombosis
and bleeding often coexist in vascular inflammatory diseases
associated with acute or chronic DIC. In DIC, hypercoagulation
simultaneously leads to thrombosis and factor depletion, which
presents as excess bleeding. Our data show how location of the
procoagulant surface is a key determinant rather than simply the
level of factors and that understanding how and where clotting
factors bind and activate is critical to delineating its role in AAA
development. Thus, up-regulating coagulation within the circu-
lation by either Alox deletion or systemic eoxPL/aPL adminis-
tration simultaneously induces a bleeding phenotype and
strongly reduces AAA (14, 17, 22).
During AAA development, complex alterations to hemostasis
were observed, and this was further modulated by eoxPL. We
note that hemostasis will also be influenced by liver synthesis of
coagulation factors and their rates of activation and clearance
from the circulation, none of which are yet characterized in the
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context of AAA development. Furthermore, which coagulation
factors are most sensitive to the actions of eoxPL in the context
of AAA development are unknown. A role for FXa has been
revealed; however, others may also play a role (SI Appendix, Fig.
S6B) (7). A recent study revealed that blocking thrombin or
FXIa could reduce hypertension and vascular remodelling in
mice, raising the possibility that multiple factors mediate the
effects of Ang II in vivo (29). In the case of FXI, a novel interaction
with GP1bα amplified thrombin activity (29). Furthermore,
blocking the interaction of GP1bα with vWF reduces thrombin
generation in platelet-rich plasma (38). Given the key role of
GP1bα in atherogenesis (39), further studies are required to de-
termine the in vivo pharmacology of eoxPL effects on coagulation
factor biology in AAA and their interactions with GP1bα.
How coagulation promotes AAA and the role of inflammation
is not clear. A recent study found that the FXa inhibitor rivar-
oxaban prevents NFkB activation in a murine model of
inflammation-driven cardiac remodeling (40). Here we found
that genetic deletion of Alox15 significantly abrogated the ability
of Ang II to elevate both IL6 and CCL2 gene expression (Fig.
5F). These data support the idea that coagulation may drive
inflammation in this model, in line with a recent report on the
role of inflammation in Ang II-dependent cardiac remodelling
(29). Future studies will characterize how blocking these path-
ways might affect coagulation and eoxPL generation.
Atherosclerosis is a well-known multimorbidity along with
other inflammatory disorders such as chronic kidney disease,
vascular dementia, diabetes, and AAA. Indeed, there is in-
creasing interest in the underlying mechanisms by which multi-
morbidities develop via common and distinct pathways. Despite
this, AAA does not normally develop in ApoE−/− but requires an
additional challenge (Ang II), beyond that which triggers ath-
erosclerosis. Thus, additional pathways are required, and we
show here a key involvement of eoxPL and coagulation. Given
the already known role of Alox15 in atherosclerosis, our findings
underscore the central role that eoxPL and Alox isoforms play in
several related forms of vascular inflammation.
In summary, we present a paradigm for AAA development,
proposing that procoagulant cell membranes from blood cells
are a driver through supporting coagulation factor activation and
inflammation. The precise mechanisms by which factors such as
FX (and other procoagulant and anticoagulant factors) regulate
AAA along with eoxPL remain to be determined, and the role of
inflammatory signaling mediated by factors requires clarification.
This research highlights pathways implicated in AAA and sug-
gests directions for future therapeutic research in this area.
Materials and Methods
Human Tissue Processing. Subjects undergoing open AAA repair were pro-
spectively recruited from the Oxford Abdominal Aortic Aneurysm (OxAAA)
study, approved by the Oxford regional ethics committee (Ethics Reference:
13/SC/0250). Every participant gave written informed consent prior to the
procedure. Full details are in SI Appendix, SI Materials and Methods.
Murine Strains and Licenses. Alox12−/− and Alox15−/− mice were crossed onto
an ApoE−/− strain on a C56BL/6 background. All animal experiments were
performed in accordance with the United Kingdom Home Office Animals
(Scientific Procedures) Act of 1986, under License (PPL 30/3150). Housing and
genotyping is in SI Appendix, SI Materials and Methods.
Atherosclerosis Quantification. Mice were fed standard chow diet and killed
via CO2 inhalation at 19 wk of age. Soft tissue samples were harvested for
histological or immunohistochemical analysis. Samples were fixed in 4% para-
formaldehyde for 48 h, which preserved tissue structure and protein expression
for sectioning. Full details are in SI Appendix, SI Materials and Methods.
Ang II Infusion, AAA Development, and Blood Pressure Recordings. Male and
female ApoE−/−, ApoE−/−/Alox12−/−, and ApoE−/−/Alox15−/− mice (19–24 wk
old) were anesthetized by inhalation with 5% isoflurane and maintained
with 2% isoflurane. Osmotic minipumps (model 1002; Charles River) deliv-
ering saline or Ang II (1 mg·kg−1 per day; Sigma-Aldrich) for 14 d were
implanted s.c. in the midscapular region under aseptic conditions. Full details
are in SI Appendix, SI Materials and Methods.
RNA Extraction, cDNA Synthesis, and Real-Time PCR. AAA tissues (weight
range 50–150 mg) were harvested and snap frozen. They were homoge-
nized, and RNA was extracted as detailed in SI Appendix, SI Materials
and Methods.
PL Liposome Preparation. Liposomes were made by extrusion in PBS, pH 7.4.
Control liposomes (aPL) contained 25.67 μg DSPC, 11.52 μg SAPE, and 2.08 μg
SAPS, and for eoxPL liposomes, 3.92 μg 12-HETE-PE was added with a re-
duced amount of SAPE (7.68 μg). Full details are in SI Appendix, SI Materials
and Methods.
Blood Lipid Analysis and Clotting Parameters. Whole blood was collected in
3.8% sodium citrate buffer via cardiac puncture and allowed to clot for 1 h
undisturbed at room temperature in a 1.5 mL Eppendorf. The blood was then
centrifuged at 2,000 × g for 10 min at 4 °C, and the serum was removed and
stored at −80 °C, before being shipped to Medical Research Council Harwell
Clinical Pathology for lipid analysis. Blood was analyzed for plasma thrombin/
antithrombin (TAT) and prothrombin time (PT) as outlined in SI Appendix, SI
Materials and Methods.
Isolation and Activation of Mouse Platelets. Mouse platelets were isolated as
described (17). Whole blood was obtained by cardiac puncture directly into a
syringe containing 150 μL of ACD [2.5% (wt/vol) trisodium citrate, 1.5% (wt/
vol) citric acid, and 100 mM glucose]. Activation is described in full in SI
Appendix, SI Materials and Methods.
Isolation and Activation of Mouse Eosinophils. Eosinophils were generated
from bone marrow isolated from 8-wk-old mice as previously described (41)
with minor modifications, and activation is described in SI Appendix, SI
Materials and Methods.
Externalization of PE or PS on the Surface of Platelets and Eosinophils. Total
and external PE/PS labeled as described in full in SI Appendix, SI Materials and
Methods (42). In brief, cultured mouse eosinophils (4 × 106 per ml) were
stimulated with ADP (40 μM) while platelets were measured basally. Full
details are provided in SI Appendix, SI Materials and Methods.
Tail Bleeding Assay. All mice were kept in constant temperature cages (20–
22 °C) and given free access to water and standard chow. Mice were
anesthetized using 5% isoflurane and maintained with 2% isoflurane, and
tail bleeding was measured as outlined in SI Appendix, SI Materials
and Methods.
Clot Formation Using Mouse Blood. To model physiological clot formation,
whole mouse blood was anticoagulated using citrate and corn trypsin in-
hibitor to prevent the contact pathway. Coagulation was initiated by
recalcification at 37 °C for up to 3 h, and the use of glassware was avoided at
all times, before the clot was harvested for lipid extraction and analysis, as
outlined in SI Appendix, SI Materials and Methods.
Harvesting and Processing of AAA Lesions for Lipidomics. Male ApoE−/− ice
(18–19 wk old) were killed via CO2 inhalation after 2-wk Ang II infusion as
outlined above. Blood was removed via cardiac puncture, and mice were
perfused with PBS containing 10 mM butylatedhydroxytoluene (BHT) and
diethylenetriaminepentaacetic acid (DTPA) to reduce autooxidation. Mice
were carefully dissected to reveal the abdominal aorta, which was recovered
and snap frozen in liquid nitrogen. Samples were stored at −80 °C until lipid
extraction, as described for clots.
Heatmap and Cytoscape Correlation. For generation of heatmaps, analyte:in-
ternal standard for each eoxPLwas plottedusing the Pheatmap package in R, as
described in SI Appendix, SI Materials and Methods. Relationships between
related lipids were visualized in Cytoscape (version 3.6.0) using Pearson cor-
relations generated with R (r > 0.8).
Statistical Analysis. Multivariate analysis was performed using SIMCA-P ver-
sion 12.0 (Umetrics) to evaluate relationships in terms of similarity or dis-
similarity among groups. PCA visualization was performed in SIMCA-P and
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the 3Dvisualization rgl package in R. All other statistics and experimental design
considerations are described in SI Appendix, SI Materials and Methods.
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